INFLUENZA B VIRUS IGG ANTIBODY

The INFLUENZA B VIRUS IGG ANTIBODY test detects immunoglobulin G (IgG) specific to Influenza B virus in a blood sample, using lab-grade serological methods (e.g., ELISA/CLIA). It measures the presence and level of IgG antibodies that indicate prior exposure or an immune response following infection or vaccination, rather than diagnosing an active influenza infection.

This test is useful for confirming past Influenza B exposure, assessing serological immunity after vaccination or illness, and supporting public health or occupational screening for at-risk groups in Dubai and across the UAE. Note that IgG typically appears 1–3 weeks after infection and may persist; for suspected acute infection, molecular tests (PCR) or IgM assays are more appropriate.

• Influenza B Virus IgG Antibody
• IgG Antibody Titre (AU/mL)
• Qualitative Result (Reactive / Non-reactive)
• Reference Cut-off / Interpretation

• After recovery from suspected Influenza B to confirm past infection
• To evaluate immune response following seasonal influenza vaccination
• For healthcare workers, caregivers, or high-risk populations assessing immunity status
• During epidemiological studies or workplace screening for prior exposure
• When investigating the cause of a previous unexplained respiratory illness

• At-home sample collection across Dubai and UAE by certified phlebotomists
• Lab-grade, reliable serology to confirm past exposure or immunity
• Fast turnaround and secure electronic reporting compatible with UAE healthcare needs
• Helps guide clinical decisions about vaccination or further testing
• Convenient for families, elderly, and individuals with mobility constraints

• At-home venous blood collection by a licensed phlebotomist or nurse
• No fasting is required prior to the test
• Inform the team about recent influenza vaccination or immunoglobulin/blood transfusion within the past 3 months
• Provide valid Emirates ID and consent for testing (parental consent for minors)